Objectives:To assess the quality of life (QV) in patients with inflammatory bowel disease (DII), and relate it to demographic data and morbidity. Methods: Cross-sectional study with 103 patients with DII, registered in the high cost pharmacy of Cuiabá -Mato Grosso, who responded to the Standard Medical Record, the general QV questionnaire SF-36 and the specific IBDQ. Results: Among 103 patients with DII, 62 had ulcerative colitis and 41 had Crohn's disease; 62% were women; 69.9% were married; 48.5% were of mixed race; 49.5% were smokers; 37.9% required surgery; and, 40.8% had active disease. We observed significant changes in QV in men, smokers and those with active disease. Conclusion: DII affect QV in several respects. Measures for maintenance of QV, psychological, social and education support should be considered for patients with DII. Keywords: Inflammatory bowel disease; Crohn's disease; Ulcerative colitis; Colitis; Quality of life RESUMOObjetivos: Avaliar a qualidade de vida (QV) de portadores de doenças inflamatórias intestinais (DII) e relacionar dados sociodemográficos e mórbidos à QV. Métodos: Estudo transversal, realizado com 103 portadores de DII, cadastrados na farmácia de alto custo de Cuiabá -Mato Grosso que responderam ao Prontuário-Padrão, ao questionário de QV geral SF36 e ao específico IBDQ. Resultados: Dentre os 103 pacientes com DII, 62 tinham retocolite ulcerativa idiopática e 41 doença de Crohn; 62% eram mulheres; 69,9%, casados; 48,5%, pardos; 49,5%, fumantes, 37,9% necessitaram de cirurgia e 40,8% apresentavam doença em atividade. Foi observada alteração significativa da QV em homens, fumantes e entre aqueles com doença em atividade. Conclusão: DII afetam a QV em diversos aspectos. Medidas para manutenção da QV, suporte psicológico, social e educacional devem ser considerados para portadores de DII. Descritores: Doença inflamatória intestinal; Doença de Crohn; Retocolite ulcerativa; Colite; Qualidade de vida RESUMEN Objetivos: Evaluar la calidad de vida (CV) de portadores de enfermedades inflamatorias intestinales (EII) y relacionar datos sociodemográficos y mórbidos a la CV. Métodos: Se trata de un estudio transversal, realizado con 103 portadores de EII, registrados en la farmacia de alto costo de Cuiabá -Mato Grosso que respondieron a la Historia Clínica-Patrón, al cuestionario de CV general SF36 y al específico IBDQ. Resultados: De los 103 pacientes con EII, 62 tenían rectocolitis ulcerosa idiopática y 41 enfermedad de Crohn; 62% eran mujeres; 69,9%, casados; 48,5%, pardos; 49,5%, fumadores, 37,9% necesitaron de cirugía y 40,8% presentaban la enfermedad en actividad. Fue observada una alteración significativa de la CV en hombres, fumadores y en aquellos con la enfermedad en actividad. Conclusión: Las EII afectan la CV en diversos aspectos. Para la manutención de la CV, deben ser considerados el soporte psicológico, social y educacional de los portadores de EII. Descriptores: Enfermedad inflamatoria intestinal; Enfermedad de Crohn; Colite ulcerosa; Colite; Calidad de vida

RESUMO: Estudos epidemiológicos recentes sugerem que a incidência da doença de Crohn (DC) e da retocolite ulcerativa (RCUI) está aumentando no

BACKGROUND: Inflammatory bowel diseases (IBD) are chronic inflammatory affections of recurrent nature whose incidence and prevalence rates have increased, including in Brazil. In long term, they are responsible for structural damage that impacts quality of life, morbidity and mortality of patients. OBJECTIVE: To describe the profile of physicians who treat IBD patients as well as the characteristics of IBD care, unmet demands and difficulties. METHODS: A questionnaire containing 17 items was prepared and sent to 286 physicians from 101 Brazilian cities across 21 states and the Federal District, selected from the register of the State Commission of the “Study Group of Inflammatory Bowel Disease of Brazil” (GEDIIB). RESULTS: The majority of the physicians who answered the questionnaire were gastroenterologists and colorectal surgeons. More than 60% had up to 20 years of experience in the specialty and 53.14% worked at three or more locations. Difficulties in accessing or releasing medicines were evident in this questionnaire, as was referrals to allied healthy professionals working in IBD-related fields. More than 75% of physicians reported difficulties in performing double-balloon enteroscopy and capsule endoscopy, and 67.8% reported difficulties in measuring calprotectin. With regard to the number of patients seen by each physician, it was shown that patients do not concentrate under the responsibility of few doctors. Infliximab and adalimumab were the most commonly used biological medicines and there was a higher prescription of 5-ASA derivatives for ulcerative colitis than for Crohn’s disease. Steroids were prescribed to a smaller proportion of patients in both diseases. The topics “biological therapy failure” and “new drugs” were reported as those with higher priority for discussion in medical congresses. In relation to possible differences among the country’s regions, physicians from the North region reported greater difficulty in accessing complementary exams while those from the Northeast region indicated greater difficulty in accessing or releasing medicines. CONCLUSION: The data obtained through this study demonstrate the profile of specialized medical care in IBD and are a useful tool for the implementation of government policies and for the Brazilian society as a whole.

Probiotics are effective to diminished inflammatory status mediated by IL-6 in experimental colitis.

Introduction: pyoderma gangrenosum (PG) is a rare and severe neutrophilic dermatosis associated with inflammatory bowel disease (IBD) and other systemic diseases such as rheumatoid arthritis and hematological malignancies. Diagnosis is based on clinical criteria and exclusion of other skin disorders. There is no gold standard for the treatment of PG; traditionally intravenous corticosteroids are used, but recently the use of drugs that inhibit tumor necrosis factor alpha (TNF-alpha) has changed the management of PG, showing great effectiveness. Case report: female patient, 23 years old, diagnosed with severe nonspecific ulcerative colitis (UC) three years ago, undergoing treatment with oral mesalamine and azathioprine. She developed PG fourteen days after hospital discharge; hospitalization was due to worsening of intestinal disease symptoms. She was successfully treated using biological therapy after unfavorable evolution with corticosteroid therapy. Conclusion: PG, a rare extraintestinal manifestation of IBD of difficult resolution that has significant impact on patient quality of life. The use of biological therapy for PG has higher efficacy in the treatment of patients decreasing wound healing time and return to daily activities.